Lymph node clues may predict immunotherapy response in esophageal cancer
NCT ID NCT07533357
First seen Apr 25, 2026 · Last updated Jun 20, 2026 · Updated 12 times
Summary
This observational study will enroll 158 adults with advanced or recurrent esophageal cancer who plan to receive PD-1 inhibitor immunotherapy. Researchers want to see if a high level of a specific immune cell type (precursor exhausted T cells, or Tpex) in cancer-free lymph nodes can better predict survival than current methods. The study does not test a new treatment but aims to improve how doctors forecast treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a better way to predict which patients will benefit from immunotherapy, helping doctors choose the right treatment earlier.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. The findings may not apply to all patients or be confirmed in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.